Synvisc one arthritis injection
BRIDGEWATER, NJ – According to a press release published by Sanofi, US, a manufacturer of medical devices, Sanofi Genzyme, a subsidiary, voluntarily recalled one large lot of Synvisc-One arthritis injections for suspected microbial contamination.
Synvisc-One, manufactured by Sanofi Genzyme, is an injection intended for the treatment of osteoarthritis. On December 11, 2017, Sanofi Genzyme issued a voluntary recall, in coordination with the United States Food & Drug Administration (FDA) of one lot of Synvisc-One arthritis injections. The specific lot number at issue is 7RSL021, which was distributed and sold to patients in the United States between October 25, 2017, and November 7, 2017.
According to Sanofi’s press release, the affected lot of the Synvisc-One injections may have had microbial contamination. If true, such contamination can place patients at risk of contracting dangerous infections that may be difficult to treat. Sanofi is requesting that all injections which are part of Lot 7RSL021 be returned to Sanofi Genzyme for further evaluation.
For patients who have already used the potentially contaminated Synvisc-One injections, they may be concerned that they are at risk of getting an infection. Such patients should consider working with their doctors to determine if any testing can rule out an infection. Because all patients are different, infections can affect them in various ways. For some patients, the infection may be mild, but for others, the infection could be severe and life-threatening.
While Sanofi Genzyme has taken the proper steps to recall the affected lot of Synvisc-One, for patients who have sustained infections which required treatment after using the arthritis injections, they may wish to pursue legal action against Sanofi Genzyme to recover compensation for damages resulting from the infection.
